Patient-Based Therapeutics

AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.

Patient Focused


rp4.jpgThe main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes. 

learn about our work

Neurodegenerative Disease Areas

Latest News

February 27, 2024

AcuraStem CEO, Sam Alworth, will present on the company's trailblazing approach to amyotrophic lateral sclerosis (ALS) therapies at the MDA Clinical & Scientific Conference on March 4th.

» Read more
February 27, 2024

AcuraStem’s Head of Target Validation, Dr. Wen-Hsuan Chang, presented an update on the company's innovative UNC13A program at the 14th Annual California ALS Research Summit on January 19, 2024

» Read more
January 30, 2024

AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trial

» Read more

Keep Up to Date with AcuraStem